Vontobel Holding’s Ocular Therapeutix OCUL Stock Holding History

Vontobel Holding’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Sell	111,368 -24,237	-18%	-$220K	﹤0.01%	789
2026 Q1	$1.15M	Buy	+135,605	New	+$1.29M	﹤0.01%	630
2025 Q4	–	Sell	-14,498	Closed	-$169K	–	1503
2025 Q3	$169K	Sell	14,498 -3,187	-18%	-$38.1K	﹤0.01%	1249
2025 Q2	$164K	Buy	17,685 +6,901	+64%	+$54K	﹤0.01%	1193
2025 Q1	$79K	Buy	+10,784	New	+$82.9K	﹤0.01%	1053
2023 Q4	–	Sell	-10,000	Closed	-$31.4K	–	1147
2023 Q3	$31.4K	Hold	10,000	–	–	﹤0.01%	1051
2023 Q2	$51.6K	Sell	10,000 -15,000	-60%	-$89.2K	﹤0.01%	1074
2023 Q1	$132K	Buy	25,000 +1,000	+4%	+$4.75K	﹤0.01%	1013
2022 Q4	$67.4K	Buy	+24,000	New	+$79.5K	﹤0.01%	1056

Other funds holding OCUL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

ELI

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Vontobel Holding's OCUL Position: Q2 2026 in Review

Vontobel Holding reduced its Ocular Therapeutix (OCUL) stake by 18% in Q2 2026, selling an estimated $220K and leaving 111,368 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #789.

Vontobel Holding first reported a position in OCUL in Q4 2022 and has held it in 9 quarters since. The position peaked at $1.15M in Q1 2026. 92 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Vontobel Holding held 111,368 shares of Ocular Therapeutix worth $1.09M as of Q2 2026.
Vontobel Holding sold 24,237 Ocular Therapeutix shares in Q2 2026, an estimated $220K.
Ocular Therapeutix made up ﹤0.01% of Vontobel Holding's portfolio in Q2 2026, its #789 holding.
Vontobel Holding first reported a position in Ocular Therapeutix in Q4 2022 and has held it in 9 quarters since.
Vontobel Holding's Ocular Therapeutix position peaked at $1.15M in Q1 2026.
92 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Vontobel Holding's 13F filing for Q2 2026, filed 3 Aug 2026.